Chin Kim

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin

Jung-Ryul Kim, W. Huh, Tae-Eun Kim, 2015, Drug design, development and therapy.

A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer

J. Roh, H. Chung, S. Rha, 2010, Investigational New Drugs.

Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study

Hyeong-Seok Lim, Yook-Hwan Noh, Yo Han Kim, 2015, Drug design, development and therapy.

Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.

Ji-Young Park, Kyoung-Ah Kim, Shin-Jung Park, 2013, Clinical therapeutics.

Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study.

Ji-Young Park, Kyoung-Ah Kim, Jonglae Lim, 2011, Clinical therapeutics.

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy

Tae Won Kim, J. Roh, H. Chung, 2012, Investigational New Drugs.

Tolerability and Pharmacokinetics of Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor-γ Agonist, After a Single Oral Administration in Healthy Female Subjects

Joo-Youn Cho, K. Yu, I. Jang, 2014, Clinical Drug Investigation.

Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers.

M. Park, Youn Nam Kim, Jangik I. Lee, 2014, Clinical therapeutics.